{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:11:25Z","timestamp":1753891885832,"version":"3.41.2"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Colorectal cancer (CRC) is a common malignant tumor worldwide. Approximately 20%\u201325% of patients have metastases at the time of initial diagnosis, and nearly half eventually develop metastatic cancer. The standard first- and second-line treatments for unresectable metastatic CRC are full-dose two-\/three-agent chemotherapy with or without a combination of molecularly targeted agents. However, many patients are ineligible for intensive therapy due to poor performance status or advanced age. TAS-102 (trifluridine\/tipiracil) in combination with bevacizumab may provide a new treatment strategy for patients with advanced CRC who are ineligible for intensive therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case report description<\/jats:title><jats:p>We report a case of a 91-year-old woman diagnosed with stage IV adenocarcinoma of the rectosigmoid junction in the presence of multiple metastases. The patient had a history of hypertension, had suffered from deep vein thrombosis of the left lower extremity, and was allergic to several drugs. Genetic testing showed multiple mutations in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS), Phosphatidylinositol-4,5-bisphosphate 3-Kinase Catalytic Subunit Alpha (PIK3CA), and Tumor Protein p53 (TP53); microsatellite stability; and a tumor mutational burden of 4.5 Mut\/Mb. The patient was diagnosed with stage IV adenocarcinoma of the rectosigmoid junction in May 2020, with a clinical stage of cTxNxM1. Without surgery, the patient received first-line treatment with capecitabine in combination with bevacizumab, which was changed to second-line treatment with TAS-102 in combination with bevacizumab after disease progression, with a progression-free survival of 10 months, achieving a significant survival benefit. Later, due to the patient\u2019s poor physical condition, no further medication was administered, and the patient died on 1 September 2022.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>TAS-102 in combination with bevacizumab for the treatment of elderly patients with metastatic CRC who are ineligible for intensive therapy is a promising treatment option.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1558470","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T05:11:34Z","timestamp":1743138694000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["TAS-102 in combination with bevacizumab for second-line treatment of metastatic colorectal cancer with a hypertensive elderly patient: a case report"],"prefix":"10.3389","volume":"15","author":[{"given":"Lingling","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xun","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongmei","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinghua","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"B1","unstructured":"International Agency for Research on Cancer: Cancer Today, All cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"J Natl Cancer Cent"},{"key":"B3","unstructured":"SEER cancer statistics factsheets: colon and rectum cancer\n          \n          \n          \n          2024"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu260","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","author":"Van Cutsem","year":"2014","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21731","article-title":"Cancer treatment and survivorship statistics, 2022","volume":"72","author":"Miller","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-014-1914-y","article-title":"Colorectal cancer surgery remains effective with rising patient age","volume":"29","author":"Nitsche","year":"2014","journal-title":"Int J Colorectal Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.04.038","article-title":"Association of age of onset of hypertension with cardiovascular diseases and mortality","volume":"75","author":"Wang","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.27.2.449","article-title":"Potentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo","volume":"27","author":"Emura","year":"2005","journal-title":"Int J Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1586\/17512433.2016.1133285","article-title":"A novel antimetabolite: TAS-102 for metastatic colorectal cancer","volume":"9","author":"Miyamoto","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/s0006-2952(00)00253-7","article-title":"Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2\u2019-deoxyribonucleosides","volume":"59","author":"Fukushima","year":"2000","journal-title":"Biochem Pharmacol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30425-4","article-title":"TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1\/2 study","volume":"18","author":"Kuboki","year":"2017","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30827-7","article-title":"TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial","volume":"21","author":"Pfeiffer","year":"2020","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.14988","article-title":"Prospective multicenter phase II study of biweekly TAS-102 and bevacizumab for metastatic colorectal cancer","volume":"41","author":"Ishizaki","year":"2021","journal-title":"Anticancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer","volume":"388","author":"Prager","year":"2023","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00334-X","article-title":"Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study","volume":"8","author":"Andr\u00e9","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.3512","article-title":"Overall survival results for trifluridine\/tipiracil plus bevacizumab vs capecitabine plus bevacizumab: Results from the phase 3 SOLSTICE study","volume":"41","author":"Andre","year":"2023","journal-title":"JCO"},{"key":"B18","first-page":"68","article-title":"CSCO diagnosis and treatment guidelines for colorectal cancer 2024","year":"2024","journal-title":"People\u2019s Med Publishing House"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21338","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2023.104487","article-title":"Strategies of nanomedicine for targeting the signaling pathways of Colorectal cancer","volume":"84","author":"Habeeb","year":"2023","journal-title":"J Drug Delivery Sci Technol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"197","DOI":"10.21147\/j.issn.1000-9604.2023.03.01","article-title":"National Health Commission guidelines for diagnosis and treatment of colorectal cancer 2023 in China (English version)","volume":"35","year":"2023","journal-title":"Chin J Cancer Res"},{"key":"B22","article-title":"When to use triplet chemotherapy as first-line treatment in metastatic colorectal cancer","volume":"17","author":"Cremolini","year":"2019","journal-title":"Clin Adv Hematol Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3747\/co.22.2337","article-title":"Palliative chemotherapy for patients 70 years of age and older with metastatic colorectal cancer: a single-centre experience","volume":"22","author":"Boss\u00e9","year":"2015","journal-title":"Curr Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-019-01485-z","article-title":"Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer","volume":"25","author":"Hashiguchi","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2016.08.006","article-title":"Efficacy and safety of bevacizumab combined with fluoropyrimidine monotherapy for unfit or older patients with metastatic colorectal cancer: A systematic review and meta-analysis","volume":"16","author":"Pinto","year":"2017","journal-title":"Clin Colorectal Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1177\/1758835918780140","article-title":"5-fluorouracil and cardiotoxicity: a review","volume":"10","author":"Sara","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70154-2","article-title":"Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial","volume":"14","author":"Cunningham","year":"2013","journal-title":"Lancet Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.3_suppl.111","article-title":"Efficacy and safety of trifluridine\/tipiracil in combination with bevacizumab in older and younger patients with refractory metastatic colorectal cancer: A subgroup analysis of the phase 3 SUNLIGHT trial","volume":"42","author":"Taieb","year":"2024","journal-title":"JCO"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad296","article-title":"Trifluridine\/tipiracil plus bevacizumab for vulnerable patients with pretreated metastatic colorectal cancer: A retrospective study (WJOG14520G)","volume":"29","author":"Kito","year":"2024","journal-title":"Oncologist"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v15.i5.902","article-title":"Oral fruquintinib combined with tegafur-gimeracil-oteracil potassium for advanced colorectal cancer to obtain longer progression-free survival: A case report","volume":"15","author":"Qu","year":"2023","journal-title":"World J Gastrointest Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1112224","article-title":"Case report: Long-term survival in a patient with metastatic colorectal cancer treated with trifluridine\/tipiracil in the third-line setting","volume":"13","author":"ELBassiouny","year":"2023","journal-title":"Front Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e15567","article-title":"Efficacy and safety of regorafenib plus biweekly TAS-102 for refractory metastatic colorectal cancer (REGTAS): A multicenter single-arm phase II trial","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1558470\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T05:12:14Z","timestamp":1743138734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1558470\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":32,"alternative-id":["10.3389\/fonc.2025.1558470"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1558470","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"article-number":"1558470"}}